Tiger Eye Capital’s UnitedHealth UNH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-1,866
Closed -$958K 30
2022
Q2
$958K Sell
1,866
-12,033
-87% -$6.04M 0.85% 10
2022
Q1
$7.09M Sell
13,899
-7,467
-35% -$3.6M 2.71% 6
2021
Q4
$10.7M Buy
21,366
+19,500
+1,045% +$8.83M 2.96% 6
2021
Q3
$729K Sell
1,866
-12,100
-87% -$5.01M 0.28% 28
2021
Q2
$5.59M Buy
13,966
+11,300
+424% +$4.51M 1.43% 23
2021
Q1
$992K Buy
2,666
+811
+44% +$281K 0.2% 37
2020
Q4
$651K Hold
1,855
0.11% 41
2020
Q3
$578K Sell
1,855
-1,016
-35% -$312K 0.14% 29
2020
Q2
$847K Hold
2,871
0.2% 30
2020
Q1
$716K Hold
2,871
0.24% 28
2019
Q4
$844K Hold
2,871
0.15% 33
2019
Q3
$624K Hold
2,871
0.16% 27
2019
Q2
$701K Sell
2,871
-15,944
-85% -$3.83M 0.15% 33
2019
Q1
$4.65M Sell
18,815
-17,552
-48% -$4.48M 1.13% 22
2018
Q4
$9.06M Sell
36,367
-15,798
-30% -$4.17M 3.83% 11
2018
Q3
$13.9M Buy
52,165
+13,363
+34% +$3.48M 2.53% 20
2018
Q2
$9.52M Sell
38,802
-9,817
-20% -$2.36M 1.92% 23
2018
Q1
$10.4M Sell
48,619
-43,895
-47% -$10M 2.29% 19
2017
Q4
$20.4M Buy
92,514
+24,514
+36% +$5.2M 3.37% 15
2017
Q3
$13.3M Buy
+68,000
New +$13.1M 1.98% 24

Other funds holding UNH

Tiger Eye Capital's UNH Position: Q3 2022 in Review

Tiger Eye Capital sold out of UnitedHealth (UNH) in Q3 2022, closing a stake of 1,866 shares — an estimated $958K sold.

Tiger Eye Capital first reported a position in UNH in Q3 2017 and held it in 20 quarters. The position peaked at $20.4M in Q4 2017. 2,994 funds tracked by Wall St. Rank hold UNH as of Q3 2022.

  • Tiger Eye Capital reported no remaining UnitedHealth position as of Q3 2022 after selling out during the quarter.
  • Tiger Eye Capital sold 1,866 UnitedHealth shares in Q3 2022, an estimated $958K.
  • Tiger Eye Capital first reported a position in UnitedHealth in Q3 2017 and held it in 20 quarters.
  • Tiger Eye Capital's UnitedHealth position peaked at $20.4M in Q4 2017.
  • 2,994 funds tracked by Wall St. Rank held UnitedHealth as of Q3 2022.

Based on Tiger Eye Capital's 13F filing for Q3 2022.